{"topic_id":"evidence_feline_hepatic_lipidosis_diet","category":"evidence","context":"---\ntopic_id: evidence_feline_hepatic_lipidosis_diet\ncategory: evidence\ntitle: \"Evidence cluster — feline hepatic lipidosis nutritional management (peer-reviewed, Europe PMC + PubMed)\"\nlang: en\nsource_file: pdf-raw/evidence/europepmc_feline_hepatic_lipidosis_diet_2026-07-22.txt\nsource: Europe PMC REST search (first-hand PMIDs) + PubMed efetch verbatim abstracts, pulled 2026-07-22\ndate_parsed: 2026-07-22\nmodel: codebuddy\nbatch: P0-EVIDENCE-8\nverified: 2026-07-22 substring_match 24/24 claims passed\npath: evidence/evidence_feline_hepatic_lipidosis_diet/01_feline_hepatic_lipidosis_diet.md\n---\n## Representative peer-reviewed studies (verbatim abstracts)\n\nThe following studies were retrieved from Europe PMC / PubMed and are reproduced verbatim. Interpretive synthesis is left to the API user.\n\n### PMID:42283012 — Multi-target synergistic mechanisms of flavonoid compounds from traditional Chinese medicine in non-alcoholic fatty liver disease: insights for human and veterinary medicine.\n- Source: Front Vet Sci 2026\n1. Front Vet Sci. 2026 May 27;13:1804773. doi: 10.3389/fvets.2026.1804773. \neCollection 2026.\n\nMulti-target synergistic mechanisms of flavonoid compounds from traditional \nChinese medicine in non-alcoholic fatty liver disease: insights for human and \nveterinary medicine.\n\nWang Y(#)(1), Wan C(#)(1), Mu L(1), Zhu A(2), Li Y(1), Liu Y(1), Bao Y(1), Bao \nF(1).\n\nAuthor information:\n(1)College of Veterinary Medicine, Inner Mongolia Agricultural University, \nHohhot, China.\n(2)Inner Mongolia Puze Animal Health Biotechnology Co., Ltd., Hohhot, China.\n(#)Contributed equally\n\nINTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic \nliver disorder characterized by dysregulated hepatic lipid metabolism, with a \ncontinuously rising global incidence and limited safe and effective therapeutic \noptions. Importantly, NAFLD-like conditions, namely hepatic lipidosis or fatty \nliver syndrome, also prevail in veterinary clinical practice, affecting \ncompanion animals (obese cats and dogs) and livestock (periparturient dairy \ncows, fattening pigs, and broiler chickens). These metabolic liver disorders are \nprimarily induced by inappropriate feeding management and metabolic stress, \nleading to reduced production performance and survival rate of animals, huge \neconomic losses to the livestock industry, and impaired health of companion \nanimals. Flavonoid compounds derived from traditional Chinese medicine (TCM) \npossess the advantages of low toxicity and multi-target pharmacological effects, \nand have emerged as promising natural agents for NAFLD amelioration.\nMETHODS: This study adopted a systematic review approach to comprehensively \ncollect, sort out, and summarize recent relevant research findings. We focused \non widely reported TCM flavonoids, including quercetin, apigenin, and luteolin, \nand systematically analyzed the diverse molecular pathways and potential \nmechanisms by which these compounds exert protective effects against NAFLD and \nveterinary fatty liver diseases.\nRESULTS: Existing research evidence demonstrates that TCM flavonoids improve \nNAFLD through multiple core regulatory pathways. These compounds reverse hepatic \nlipid metabolism disorders by activating the AMPK/SIRT1 and PPARα signaling \npathways, inhibit lipogenesis by suppressing the key lipogenic factor SREBP-1c, \nand accelerate lipid catabolism by promoting fatty acid β-oxidation. In \naddition, flavonoids effectively alleviate hepatic oxidative stress, inhibit \ninflammatory responses, and delay the progression of liver fibrosis. \nFurthermore, they exert protective effects via regulating novel mechanisms, \nincluding cellular autophagy, ferroptosis, and intestinal microbiota \nhomeostasis.\nDISCUSSION: The multi-target and systematic regulatory characteristics of TCM \nflavonoids make them excellent candidate natural drugs for NAFLD intervention in \nboth human and veterinary medicine. Nevertheless, several limitations and \nchallenges remain in current research, including low bioavailability of \nflavonoids and unclear synergistic effects among different flavonoid components. \nFuture studies should focus on improving the bioavailability of flavonoids, \nelucidating their synergistic molecular mechanisms, and exploring \nspecies-specific pharmacokinetic characteristics in cats, dogs, and cattle. \nMoreover, the development of practical and palatable preparations such as feed \nadditives is essential to promote the clinical translation and large-scale \napplication of flavonoids for the prevention and treatment of NAFLD in human and \nveterinary clinical practice.\n\nCopyright © 2026 Wang, Wan, Mu, Zhu, Li, Liu, Bao and Bao.\n\nDOI: 10.3389/fvets.2026.1804773\nPMCID: PMC13251695\nPMID: 42283012\n\nConflict of interest statement: Author AZ was employed by Inner Mongolia Puze \nAnimal Health Biotechnology Co., Ltd. The remaining author(s) declared that this \nwork was conducted in the absence of any commercial or financial relationships \nthat could be construed as a potential conflict of interest.\n- Abstract (verbatim excerpt): \nJOURNAL:Front Vet Sci 2026\n1. Front Vet Sci. 2026 May 27;13:1804773. doi: 10.3389/fvets.2026.1804773. \neCollection 2026.\n\nMulti-target synergistic mechanisms of flavonoid compounds from traditional\n\n### PMID:42188883 — Evaluation of Serum Homocysteine and High-Sensitivity Cardiac Troponins in Cats with Hepatic Lipidosis: An Observational Clinical Study.\n- Source: Vet Sci 2026\n1. Vet Sci. 2026 Apr 23;13(5):413. doi: 10.3390/vetsci13050413.\n\nEvaluation of Serum Homocysteine and High-Sensitivity Cardiac Troponins in Cats \nwith Hepatic Lipidosis: An Observational Clinical Study.\n\nTunç AC(1), Ayvazoğlu C(2), Kızıltepe Ş(3), Bayendur SH(1), Acar A(1).\n\nAuthor information:\n(1)Department of Internal Medicine, Faculty of Veterinary Medicine, Afyon \nKocatepe University, 03200 Afyonkarahisar, Turkey.\n(2)Department of Laboratory and Veterinary Health, Nihat Delibalta Göle \nVocational School, Ardahan University, 75002 Ardahan, Turkey.\n(3)Department of Laboratory and Veterinary Health, Tuzluca Vocational School, \nIğdır University, 76000 Iğdır, Turkey.\n\nFeline hepatic lipidosis (FHL) is a life-threatening, common hepatobiliary \ndisease characterized by massive triglyceride accumulation in the liver, often \ntriggered by anorexia and negative energy balance in cats. This condition causes \nsevere metabolic stress that may secondarily impact myocardial integrity. This \nobservational clinical study evaluated serum homocysteine (Hcy) and \nhigh-sensitivity cardiac troponins (hs-cTnI, hs-cTnT) to assess secondary \nmyocardial injury and their prognostic value in FHL. Fifty cats, comprising 30 \nwith naturally occurring FHL and 20 healthy controls, were included. Serum Hcy, \nhs-cTnI, and hs-cTnT concentrations were measured using feline-specific ELISA \nkits, and routine biochemical parameters, alongside hospitalization times, were \nrecorded. Results indicated that Hcy, total bilirubin, and liver enzymes were \nsignificantly elevated in the FHL group compared to controls (p < 0.001). \nHowever, hs-cTnI and hs-cTnT levels did not differ significantly between the \ngroups. Notably, Hcy exhibited a strong positive correlation with \nhospitalization time (r = 0.89, p < 0.001). The absence of significant hs-cTn \nelevations suggests the feline myocardium remains largely resistant to acute \nnecrosis during FHL. Nevertheless, relative hyperhomocysteinemia is a powerful \nprognostic biomarker for prolonged hospitalization in affected cats.\n\nDOI: 10.3390/vetsci13050413\nPMCID: PMC13211653\nPMID: 42188883\n\nConflict of interest statement: The authors declare no conflicts of interest.\n- Abstract (verbatim excerpt): \nJOURNAL:Vet Sci 2026\n1. Vet Sci. 2026 Apr 23;13(5):413. doi: 10.3390/vetsci13050413.\n\nEvaluation of Serum Homocysteine and High-Sensitivity Cardiac Troponins in Cats \nwith Hepatic Lipidosis: An Obser\n\n### PMID:42188039 — Lipidomic Signatures in Feline Disease: A PRISMA-Guided Systematic Review.\n- Source: Metabolites 2026\n1. Metabolites. 2026 May 15;16(5):330. doi: 10.3390/metabo16050330.\n\nLipidomic Signatures in Feline Disease: A PRISMA-Guided Systematic Review.\n\nFontes AC(1), Silva CS(1)(2), Matos AC(1), Dias IR(1)(2), Peixoto F(3)(4), \nOliveira MM(3)(4), Domingues MR(5)(6), Viegas CA(1)(2)(7).\n\nAuthor information:\n(1)Department of Veterinary Sciences, School of Agricultural and Veterinary \nSciences (ECAV), University of Trás-os-Montes and Alto Douro, 5000-801 Vila \nReal, Portugal.\n(2)Animal and Veterinary Research Center (CECAV)-AL4AnimalS, University of \nTrás-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal.\n(3)Chemistry Center of Vila Real, University of Trás-os-Montes and Alto Douro, \n5000-801 Vila Real, Portugal.\n(4)RISE-Health-Health Research Network, Faculty of Medicine, University of \nPorto, 4099-002 Porto, Portugal.\n(5)CESAM, Departament of Chemistry, University of Aveiro, Campus Universitário \nde Santiago, 3810-193 Aveiro, Portugal.\n(6)Mass Spectrometry Centre, LAQV-REQUIMTE, Department of Chemistry, University \nof Aveiro, 3810-193 Aveiro, Portugal.\n(7)CIVG-Vasco da Gama Research Center, University School Vasco da Gama (EUVG), \nCampus Universitário, Avenida José Rodrigues Sousa Fernandes, 3020-210 Coimbra, \nPortugal.\n\nBackground/Objectives: Lipidomics has become a key component of systems biology, \nenabling comprehensive characterisation of lipid species and their roles in \nhealth and disease. As regulators of membrane architecture, energy balance, \ninflammation, and cellular signalling, lipids offer a powerful framework for \nunderstanding metabolic dysfunction. In veterinary medicine, however, lipidomics \nremains comparatively underdeveloped. In cats, lipid metabolism is central to \ndisorders such as hepatic lipidosis, cystitis, obesity, diabetes mellitus, and \nchronic inflammatory enteropathies, yet available data remain limited. This \nsystematic review synthesised current evidence on lipidomics and lipid-focused \nprofiling in feline disease and identified lipid alterations with potential \nclinical relevance. Methods: Following PRISMA 2020 guidelines, PubMed, \nScienceDirect, and Scopus were searched for original studies (1994-2026) \nevaluating lipidomics or lipid-focused profiling in cats. Eligible studies \nassessed lipid species, fatty acids, lipid mediators, or lipoproteins in disease \nor physiological states. Owing to methodological heterogeneity, findings were \nsynthesised narratively. Results: Seventeen studies met inclusion criteria, \ncovering hepatic, urinary, gastrointestinal, renal, neurological, oncological, \nmetabolic, and pharmacologically modulated conditions. Recurring alterations \ninvolved lipoproteins, triglycerides, phospholipids, sphingolipids, fatty acids, \nand oxylipins. More consistent patterns emerged in hepatic lipidosis, where \nlipoprotein disturbances may aid diagnosis; in lower urinary tract disease, \nwhere PUFA-derived oxylipins differentiated bacterial from idiopathic cystitis; \nand in obesity, where phospholipid and triglyceride shifts reflected metabolic \nrisk. Fatty acid remodelling in chronic enteropathies aligned with mucosal \ninflammation, while sphingolipid changes in neurological disease correlated with \nseverity. Heterogeneity in analytical platforms, dietary control, and study \ndesign limited comparability. Conclusions: Feline lipidomics reveals \nbiologically meaningful alterations with emerging diagnostic and prognostic \nvalue. Although still developing, lipid-focused approaches may enhance disease \ncharacterisation and support translational research. Larger, standardised \nstudies and robust reference datasets are needed to validate lipid signatures \nfor clinical implementation.\n\nDOI: 10.3390/metabo16050330\nPMCID: PMC13208954\nPMID: 42188039\n\nConflict of interest statement: The authors state no conflicts of interest.\n- Abstract (verbatim excerpt): \nJOURNAL:Metabolites 2026\n1. Metabolites. 2026 May 15;16(5):330. doi: 10.3390/metabo16050330.\n\nLipidomic Signatures in Feline Disease: A PRISMA-Guided Systematic Review.\n\nFontes AC(1), Silva CS(1)(2),\n\n### PMID:42022391 — From pathogenesis to prevention: an update on the management of obesity and its associated comorbidities in cats.\n- Source: Front Vet Sci 2026\n1. Front Vet Sci. 2026 Apr 7;13:1797197. doi: 10.3389/fvets.2026.1797197. \neCollection 2026.\n\nFrom pathogenesis to prevention: an update on the management of obesity and its \nassociated comorbidities in cats.\n\nWang H(1), Wang W(1), Zhang Y(1), Yao J(1)(2), Liu Y(1), Pan L(1), Wang R(3), \nWang J(4), Xia Z(4), Chen L(1), Xiong W(1)(3).\n\nAuthor information:\n(1)Food Laboratory of Zhongyuan, Luohe, China.\n(2)College of Food and Bioengineering, Zhengzhou University of Light Industry, \nZhengzhou, China.\n(3)Key Laboratory of Precision Nutrition and Food Quality, Department of \nNutrition and Health, China Agricultural University, Beijing, China.\n(4)College of Veterinary Medicine, China Agricultural University, Beijing, \nChina.\n\nOverweight and obesity represent the most common nutritional disorder in \ndomestic cats and constitute a significant global health issue. In this review, \nwe synthesize current knowledge on the determinants, diagnosis, pathophysiology, \ncomplications, and comprehensive management of feline obesity. Feline overweight \nand obesity have a complex and multifactorial pathogenesis, arising from an \ninterplay of intrinsic factors (e.g., genetic predisposition, age, sex, \nneutering status) and extrinsic factors (e.g., environment, owner behavior). The \ncondition is characterized by a state of chronic low-grade systemic \ninflammation, endocrine dysregulation, insulin resistance, and hyperlipidemia, \nwhich collectively elevate the risk of numerous comorbidities, including \ndiabetes mellitus, osteoarthritis, urinary tract disorders, dermatopathies, \ncardiomyopathy, and respiratory diseases, ultimately compromising life \nexpectancy. This means that early detection and examination of excess body \nweight are crucial to treatment and prevention; at the same time, weight loss \nshould be centered around personalized nutritional intervention, combined with \nbehavioral correction measures such as regular feeding schedules and increased \nphysical exercise. Furthermore, maintaining good communication between \nclinicians and the pet owners, as well as continuous monitoring, is the key to \nachieving effective weight loss. Future research is needed to move beyond \ncurrent reactive models and embrace a focus on metabolic health over weight, \nprediction over reaction, and pathogenesis over symptomatology, aiming for \npreemptive strategies that improve feline healthspan.\n\nCopyright © 2026 Wang, Wang, Zhang, Yao, Liu, Pan, Wang, Wang, Xia, Chen and \nXiong.\n\nDOI: 10.3389/fvets.2026.1797197\nPMCID: PMC13095525\nPMID: 42022391\n\nConflict of interest statement: The author(s) declared that this work was \nconducted in the absence of any commercial or financial relationships that could \nbe construed as a potential conflict of interest.\n- Abstract (verbatim excerpt): \nJOURNAL:Front Vet Sci 2026\n1. Front Vet Sci. 2026 Apr 7;13:1797197. doi: 10.3389/fvets.2026.1797197. \neCollection 2026.\n\nFrom pathogenesis to prevention: an update on the management of obesity and it\n\n### PMID:41448592 — Effect of Parenteral Amino Acid Composition on Hyperammonemia in a Cat with Hepatic Lipidosis.\n- Source: J Am Anim Hosp Assoc 2026\n1. J Am Anim Hosp Assoc. 2026 Jan 1;62(1):38-42. doi: 10.5326/JAAHA-MS-7508.\n\nEffect of Parenteral Amino Acid Composition on Hyperammonemia in a Cat with \nHepatic Lipidosis.\n\nPark J, Kang BT, Lee Y, Yun T, Kim H, Chae Y.\n\nAn 8 yr old spayed female domestic shorthair presented with a 1 wk history of \nanorexia and lethargy. Cytological examination of the liver using fine-needle \naspiration revealed numerous adipocytes, confirming hepatic lipidosis. The cat \nwas hospitalized for treatment; subsequently, the clinical signs and blood \nanalysis results improved. On day 17, the nasoesophageal tube was removed \nbecause of recovery of appetite and vitality. However, owing to insufficient \nvoluntary food intake, partial parenteral nutrition (PPN) was initiated using an \namino acid solution with a low branched-chain amino acid (BCAA)/aromatic amino \nacid (AAA) ratio and arginine deficiency. Within 24 hr of PPN administration, \nneurological signs were observed, including vocalization, panting, \nhyperactivity, and a subsequent comatose state. Although hepatic encephalopathy \nwas considered, there was limited evidence of hepatic failure. The clinical \ncourse was most consistent with acute hyperammonemia secondary to arginine \ndeficiency, although a contributing role of the low BCAA/AAA ratio cannot be \nexcluded. This case suggests that amino acid PPN with arginine deficiency and a \nlow BCAA/AAA ratio may contribute to neurological signs in cats, underscoring \nthe importance of careful amino acid selection in nutritional formulations.\n\nDOI: 10.5326/JAAHA-MS-7508\nPMID: 41448592 [Indexed for MEDLINE]\n- Abstract (verbatim excerpt): \nJOURNAL:J Am Anim Hosp Assoc 2026\n1. J Am Anim Hosp Assoc. 2026 Jan 1;62(1):38-42. doi: 10.5326/JAAHA-MS-7508.\n\nEffect of Parenteral Amino Acid Composition on Hyperammonemia in a Cat with \nHepatic Li\n\n### PMID:41742558 — Preliminary metabolic characterization of hepatic lipidosis in cats using liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry: pathway insights and candidate biomarkers.\n- Source: J Vet Intern Med 2026\n1. J Vet Intern Med. 2026 Jan 21;40(1):aalaf091. doi: 10.1093/jvimsj/aalaf091.\n\nPreliminary metabolic characterization of hepatic lipidosis in cats using liquid \nchromatography-mass spectrometry and gas chromatography-mass spectrometry: \npathway insights and candidate biomarkers.\n\nXu R(1), Yang Y(2), Bu F(1), Liu L(1), Liu Z(1), Wang X(1), Feng S(1), Zhao \nC(1).\n\nAuthor information:\n(1)College of Veterinary Medicine, Anhui Agricultural University, Hefei, China.\n(2)College of Animal Science and Technology, Shanxi Agricultural University, \njinzhong, China.\n\nBACKGROUND: Feline hepatic lipidosis (FHL) lacks well-defined metabolic \nbiomarkers and mechanistic understanding.\nHYPOTHESIS/OBJECTIVES: Clarify the metabolic biomarkers and mechanisms of FHL.\nANIMALS: Two groups of cats were analyzed: 14 cats (7 FHL cases and 7 healthy \ncontrols) for liver metabolomics, and 60 cats (10 FHL cases and 50 healthy \ncontrols) for blood 3-hydroxybutyrate (3-HB) testing.\nMETHODS: Hepatic lipidosis was confirmed by histopathological assessment and \nultrasonography. Untargeted metabolomics was performed using gas \nchromatography-mass spectrometry (GC-MS) and liquid chromatography-mass \nspectrometry (LC-MS), with pathway analysis using MetaboAnalyst 5.0. Serum 3-HB \nwas quantified using an enzymatic assay. Statistical analysis included principal \ncomponent analysis, orthogonal partial least squares discriminant analysis, \ncross-validation, permutation tests, and F₁ score evaluation for model \nvalidation.\nRESULTS: Gas chromatography-mass spectrometry identified four metabolites with \nvariable importance in projection > 1 (bootstrap 95% stability range, 0.9-1.3) \nand < 0.05, whereas LC-MS identified 243 differentially abundant metabolites \n(101 upregulated, 142 downregulated), with 19 demonstrating diagnostic potential \n(area under the curve [AUC] > 0.7). Pathway analysis identified perturbations in \nvitamin B6 metabolism (P = .003) and fructose/mannose metabolism (P < .001). \nSerum 3-HB underwent analytical validation in 60 specimens (10 FHL cases, 50 \nhealthy controls), which identified concordant hepatic and systemic increases in \nFHL. At the optimal cutoff (>2.43 mmol/L), it achieved an AUC of 0.86 (95% \nconfidence interval [CI], 0.65-1.00) with 92% sensitivity (95% CI, 89%-100%) and \n88% specificity (95% CI, 74%-100%) in distinguishing FHL from normal liver under \ncontrolled laboratory conditions.\nCONCLUSIONS AND CLINICAL IMPORTANCE: Preliminary data suggest FHL involves \ndysregulated fatty acid and vitamin B6 metabolism. Although serum 3-HB shows \npromise, future studies should include disease controls (eg, cholangitis, \nhepatitis) to establish specificity. These findings provide foundational \ninsights for mechanistic research.\n\n© The Author(s) 2026. Published by Oxford University Press on behalf of the \nAmerican College of Veterinary Internal Medicine.\n\nDOI: 10.1093/jvimsj/aalaf091\nPMCID: PMC12866907\nPMID: 41742558\n\nConflict of interest statement: The authors declare no conflicts of interest.\n- Abstract (verbatim excerpt): \nJOURNAL:J Vet Intern Med 2026\n1. J Vet Intern Med. 2026 Jan 21;40(1):aalaf091. doi: 10.1093/jvimsj/aalaf091.\n\nPreliminary metabolic characterization of hepatic lipidosis in cats using liquid \nchromat\n\n","sources":[],"tokens_estimated":3408,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}